In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Mannheim Corp.

Division of Roche

Latest From Boehringer Mannheim Corp.

Adrenomed Treads A New Path In Septic Shock

German firm Adrenomed has received new funding to push its innovative antibody for septic shock further into development. The company talks to Scrip about how it works, and why it won’t allow the asset to be a victim of strategic decision making.

Cardiovascular Financing

Perrigo Counts 32 Billion Reasons To Reject Mylan Offers

In addition to announcing it to turned down Mylan’s offer of $205 per share or roughly $28.9 billion, Perrigo reports a 41% increase in adjusted net income to a company-record $248.5 million in its latest quarter. The firm plans to launch a generic of Sanofi’s Nasacort 24 HR in time for the 2015 allergy season.

Consumer BioPharmaceutical

Perrigo Counts 32 Billion Reasons To Reject Mylan Offers

In addition to announcing it to turned down Mylan’s offer of $205 per share or roughly $28.9 billion, Perrigo reports a 41% increase in adjusted net income to a company-record $248.5 million in its latest quarter. The firm plans to launch a generic of Sanofi’s Nasacort 24 HR in time for the 2015 allergy season.

Consumer BioPharmaceutical

Nanogen Stakes A Shape-Shifting Market

Newly abundant genomic data is driving formation of all sorts of technology-based businesses. But markets for new tools are already chaotic and competitive, in part because customers know they've got many choices. Nanogen is in the thick of it. Pharmaceutical researchers weren't so interested in the firm's low-density gene chips, so the firm is now focusing on the clinical diagnostics market where managers believe flexible, accurate NanoChips will be better appreciated. The trouble is, the long-foretold market for molecular diagnostics still barely exists. On one hand, market immaturity spells opportunity for Nanogen as an early entrant, but it also means the company has to bushwhack a new path for its technology. It's not easy. For now, Nanogen is marketing its system to researchers in clinical diagnostic labs, university hospitals and government institutions-scientists at the cutting edge, who may become key content developers. The firm is also working to better serve drug makers. The company's customers display little loyalty yet: they're eager to try other new technologies too. Nanogen is betting that the superiority of its system will win hearts and minds as the market for molecular diagnostics takes shape.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Roche
  • Senior Management
  • Dennert Ware, Pres., CEO
  • Contact Info
  • Boehringer Mannheim Corp.
    Phone: (317) 845-2000
    9115 Hague Rd.
    P.O. Box 50100 Indianapolis, IN 46250
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register